Fate Therapeutics Inc (FATE)

[jondoeuk]

BGNE said its four-target NK cell therapy collaboration with Shoreline Bio is over https://ir.beigene.com/filings-financials/sec-filings//?shortDesc=Annual%20Report&format=convpdf&secFilingId=d616de2c-8830-43ea-8b09-bab3c88574dd

Since that, Shoreline has been working on AI/ML for R&D (gene editing and protein design). Automation for R&D (iPSC culture and clone screening, effector cell differentiation and testing). Automation for RHA compliant gene editing (imaging and feeding of clones, clone picking and clone expansion). Automation for sale-up and manufacturing (end-to-end process, smart manufacturing and initial to commercial scale production).